GlaxoSmithKline names new CEO
From Times Wire Services
GlaxoSmithKline named Andrew Witty as its chief executive, ending a yearlong internal competition to succeed Jean-Pierre Garnier, who retires next year.
Witty, 43, the current head of European pharmaceuticals for GlaxoSmithKline, was chosen over Chief Operating Officer David Stout and the president of U.S. pharmaceuticals, Chris Viehbacher, for the top post at the world’s No. 2 drug maker.
Analysts and investors have been speculating about Garnier’s replacement since he extended his contract at Glaxo until May to see it through the rollout of key drugs.
